The KRAS-variant is a new class of genetic marker that predicts increased cancer risk and unique treatment response to common cancer therapies, as has been shown in Ovarian, Colon, Head and Neck, and Non-Small Cell Lung (NSCLC) clinical trials. The unique biology of the KRAS-variant affords great promise for both preventing and curing cancer in individuals with this inherited mutation.

Personalized Medicine

Cancer therapies are chosen based on results of studies of groups of patients. There has been little information available to help identify how individuals within the group respond. The KRAS-variant has been shown to significantly subgroup patients into responders or non-responders to therapies being used today as standard of care. Knowing a patient’s unique genetic make up affords the opportunity to personalize cancer therapy and ultimately get better results with improved progression free and overall survival. This is critical not only for first line therapy, but certainly when choosing a treatment for second and third line therapy.

Cancer Risk

The KRAS-variant predicts an up to six-fold increase of breast and ovarian cancer risk in women, as well as an increased risk of non-small cell lung cancer. Knowing a patient’s KRAS-variant status is an additional piece of information to help direct decisions for screening and prevention.

Radiogenomics

Up to 90% of cancer patients receive radiation therapy as part of their treatment. Currently, there are no biomarkers used to identify patients that achieve the greatest benefit from radiation, versus those that have sensitivities that may outweigh the benefits. MiraDx is developing a panel of such biomarkers, including the KRAS-variant, as well as performing individual patient testing to predict radiosensitivity.

Order kits

Stay up to date on the latest research through our e-newsletter